

Accepted Manuscript

Title: Pharmacovigilance in pediatrics

Author: Émilie Bouquet Kristina Star Annie Pierre
Jonville-Béra Geneviève Durrieu

PII: S0040-5957(18)30017-9
DOI: <https://doi.org/doi:10.1016/j.therap.2017.11.012>
Reference: THERAP 247

To appear in:

Received date: 15-10-2017
Accepted date: 15-11-2017

Please cite this article as: Émilie Bouquet Kristina Star Annie Pierre
Jonville-Béra Geneviève Durrieu Pharmacovigilance in pediatrics (2018),
<https://doi.org/10.1016/j.therap.2017.11.012>



This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Thérapie

Rubrique : Pediatric pharmacology/Drugs and children

Numéro 2 mars avril 2018

Pharmacovigilance in pediatrics

Pharmacovigilance in pediatrics

Émilie Bouquet ^a, Kristina Star ^{b,c}, Annie Pierre Jonville-Béra ^a, Geneviève Durrieu ^{d,*}

^a *Department of clinical pharmacology and regional pharmacovigilance center, university hospital, CHRU Tours, 37044 Tours, France*

^b *Uppsala monitoring centre, 75140 Uppsala, Sweden*

^c *Department of public health and caring sciences, Uppsala university, 75105 Uppsala, Sweden*

^d *Department of medical and clinical pharmacology, Toulouse university hospital, faculty of medicine, 31000 Toulouse, France*

Received 15 October 2017; accepted 15 November 2017

*Corresponding author. Department of medical and clinical pharmacology, Toulouse university hospital, faculty of medicine, 37 allées Jules Guesde, 31000 Toulouse, France.

E-mail adress: genevieve.durrieu@univ-tlse3.fr (G. Durrieu)

Summary

The characteristics of pharmacology and drug evaluation in the pediatric age group highlight the necessity for the pharmacovigilance community to adjust to the specific features of children. At the time of marketing a medicinal product intended for children, the product's safety profile is

Download English Version:

<https://daneshyari.com/en/article/8544289>

Download Persian Version:

<https://daneshyari.com/article/8544289>

[Daneshyari.com](https://daneshyari.com)